Xospata Prices, Coupons, Copay Cards & Patient Assistance
Xospata (gilteritinib) is a member of the multikinase inhibitors drug class and is commonly used for Acute Myeloid Leukemia.
The cost for Xospata 40 mg oral tablet is around $30,946 for a supply of 90 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Xospata is available as a brand name drug only, a generic version is not yet available. View generic Xospata availability for more details.
Xospata prices
Oral Tablet
40 mg
Xospata oral tablet
from $30,945.80
for 90 tablets
Quantity | Per unit | Price |
---|---|---|
90 | $343.84 | $30,945.80 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Xospata Coupons, Copay Cards and Rebates
Xospata offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Xospata Patient Savings Program
Eligible commercially insured patients may pay $0 per prescription; patients enrolled in the program for a 12-month period.
- Applies to:
- Xospata
- Number of uses:
- Per 12 month period
Form more information phone: 844-632-9272 or Visit website
Patient Assistance & Copay Programs for Xospata
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Xospata (gilteritinib) Tablet
More information please phone: 866-316-7263 Visit Website
Provider: Astellas Pharma Support Solutions: XOSPATA
Eligibility requirements:- Must be uninsured or rendered uninsured
- Not disclosed
- FDA-approved diagnosis
- Must have a verifiable US shipping address and be treated by US Doctor
- Please visit www.astellaspharmasupportsolutions.com for more information This program also provides copay assistance. Support offered to patients who are prescribed Xospata.
- Xospata (gilteritinib) Tablet
More information please phone: 844-632-9272 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Xospata (gilteritinib)
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español